LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)

Alexander Stein(Universität Hamburg), Mascha Binder(Universität Hamburg), Lisa Paschold, Joseph Tintelnot(Universität Hamburg), Anke Reinacher‐Schick(Ruhr University Bochum), Lutz Jacobasch(Orthopädische Praxis), Daniel Pink(Universitätsmedizin Greifswald), Stefan Kubicka(Medizinische Hochschule Hannover), S-E. Al-Batran(Krankenhaus Nordwest), Thomas J. Ettrich(Universität Ulm), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Udo Lindig(Jena University Hospital), Axel Hinke, Jorge Riera Knorrenschild(Philipps University of Marburg), Albrecht Kretzschmar(Roche (Switzerland)), M. Sinn(Universität Hamburg), Sylvie Lorenzen(Technical University of Munich), S. Hegewisch Becker(Eppendorf (Germany)), Eray Goekkurt(Sorbonne Université)
Annals of Oncology
September 1, 2021
10.1016/j.annonc.2021.08.2134
Cited by 10

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k